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Abstract
 
Paracrine effect of transforming growth factor-
 
b
 
1 (TGF-
 
b
 
1)
on autoimmune insulitis and diabetes was studied by trans-
genic production of the active form of porcine TGF-
 
b
 
1
(pTGF-
 
b
 
1) in pancreatic islet (islet) 
 
a
 
 cells in nonobese diabe-
tic (NOD) mice under the control of rat glucagon promoter
(RGP) (NOD-RGP-TGF-
 
b
 
1). None of 27 NOD-RGP-TGF-
 
b
 
1 mice developed diabetes by 45 wk of age, in contrast to
40 and 71% in male and female nontransgenic mice, respec-
tively. None of the NOD-RGP-TGF-
 
b
 
1 mice developed dia-
betes after cyclophosphamide (CY) administration. Adop-
tive transfer of splenocytes of NOD-RGP-TGF-
 
b
 
1 mice to
neonatal NOD mice did not transfer diabetes after CY ad-
ministration. Adoptive transfer of three types of diabeto-
genic lymphocytes to NOD-RGP-TGF-
 
b
 
1 and nontransgenic
mice after CY administration led to the lower incidence of
diabetes in NOD-RGP-TGF-
 
b
 
1 mice versus that in non-
transgenic mice: 29 vs. 77% for diabetogenic splenocytes, 25
vs. 75% for islet 
 
b
 
 cell–specific Th1 clone cells, and 0 vs.
50% for islet 
 
b
 
 cell–specific CD8
 
1
 
 clone cells, respectively.
Based on these, it is concluded that autoimmune diabetes in
NOD mice is not a systemic disease and it can be completely
prevented by the paracrine TGF-
 
b
 
1 in the islet compart-
ment through protection against CD4
 
1
 
 and CD8
 
1
 
 effector
lymphocytes. (
 
J. Clin. Invest.
 
 1998. 102:499–506.) Key
words: nonobese diabetic (NOD) mice 
 
•
 
 pancreatic islets 
 
•
 
rat glucagon promoter (RGP) 
 
•
 
 adoptive transfer 
 
•
 
 CD4
 
1
 
and CD8
 
1
 
 T cells
 
Introduction
 
Autoimmune insulitis and diabetes in nonobese diabetic
(NOD)
 
1
 
 mice (1, 2) are regulated not only by helper T lympho-
cytes (CD4
 
1
 
, Th) including Th1 and Th2, and cytotoxic T
(CD8
 
1
 
) lymphocytes, but also by cytokines including IFN-
 
g
 
,
IL-2, -4, -10, -12, and TGF-
 
b
 
1 (1). TGF-
 
b
 
1, which does not be-
long to either Th1 or Th2 cytokines, inhibits proliferation of all
T cell subsets (3) and B lymphocytes (4), and it suppresses nat-
ural killer cell activity (5) and IFN-
 
g
 
 and -
 
a
 
 production (6, 7).
Multiorgan inflammation with excessive lymphocytic infiltra-
tion in TGF-
 
b
 
1 null mice proved the antiinflammatory nature
of TGF-
 
b
 
1 (8, 9). TGF-
 
b
 
1 mRNA appears just before the nat-
ural remission of Th1-mediated experimental autoimmune
neuritis (10), and experimental autoimmune encephalitis (EAE)
is prevented by the systemic administration of TGF-
 
b
 
1 (11, 12)
and aggravated by TGF-
 
b
 
1 antibody (13). Regulatory CD4
 
1
 
Th3 cells (14) or regulatory CD8
 
1
 
 cells (15) which dominantly
secrete TGF-
 
b
 
1 mediate the oral tolerance by the low dose
myelin basic protein and proteolipid protein for EAE (16, 17)
or insulin for lymphocytic choriomeningitis virus (LCMV)-
induced autoimmune insulitis and diabetes (18).
Although transgenic (Tg) expression of IL-4 in pancreatic
islet (islet) 
 
b
 
 cells (19) suppressed autoimmune insulitis and
completely abrogated diabetes in NOD mice, islet 
 
b
 
 cell trans-
genics for porcine TGF-
 
b
 
1 (pTGF-
 
b
 
1) had chronic exocrine
pancreatitis, accumulation of extracellular matrix, and disorga-
nization of islets (20, 21). TGF-
 
b
 
1 in islet 
 
b
 
 cell double trans-
genics for pTGF-
 
b
 
1 and LCMV GP protein did not protect
these mice from LCMV-induced autoimmune insulitis and dia-
betes (22). Thus, it is not known whether autoimmune insulitis
and diabetes in NOD mice can be prevented by the Tg expres-
sion of TGF-
 
b
 
1. To understand the immunosuppressive role of
Tg paracrine TGF-
 
b
 
1 for autoimmune diabetes in NOD mice,
we produced NOD-RGP-TGF-
 
b
 
1 mice in which the active
form pTGF-
 
b
 
1 with the potent immunosuppressive activities
on murine cells (23) was expressed in islet 
 
a
 
 cells without di-
rectly manipulating islet 
 
b
 
 cells. We report complete abroga-
tion of diabetes in NOD-RGP-TGF-
 
b
 
1 mice and protection by
the Tg paracrine TGF-
 
b
 
1 against adoptively transferred diabe-
tes by effector lymphocytes including diabetogenic spleno-
cytes, islet 
 
b
 
 cell–specific CD4
 
1
 
 Th1, and CD8
 
1
 
 clone cells.
 
Methods
 
Production of NOD-RGP-TGF-
 
b
 
1 mice.
 
The replacement with mu-
tagenesis of cysteine at 223 and 225 in the latent TGF-
 
b
 
1 with serine
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1. 
 
Abbreviations used in this paper:
 
 BG, blood glucose; CD8
 
1
 
, cyto-
toxic T; CY, cyclophosphamide; EAE, experimental autoimmune en-
cephalitis; islet, pancreatic islet; LCMV, lymphocytic choriomeningi-
tis virus; mTGF-
 
b
 
1, murine TGF-
 
b
 
1; NOD, nonobese diabetic;
NOD-RGP-TGF-
 
b
 
1, transgenic NOD mice in which pTGF-
 
b
 
1 was
expressed in islet 
 
a
 
 cells; pTGF-
 
b
 
1, the active form of porcine TGF-
 
b
 
1; Tg, transgenic; Th, CD4
 
1
 
 helper T.
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residues produced the active pTGF-
 
b
 
1, with its activity detected with-
out acid treatment (24). To make a transgene construct, the 1,320-bp
pTGF-
 
b
 
1 sequence was cut out from a plasmid of pPK9a (25) pro-
vided by Dr. Greenberg (Manitoba Institute of Cell Biology), with
BglII, and subcloned into a BamHI site of pBluescript (pRB601). Af-
ter deleting the EcoRI site from pRB601 with ClaI and PstI digestion,
a SalI-NotI fragment of 1,350 bp was subcloned into a SalI-NotI site
in the transgene vector as described previously (26). The resulting
transgene construct (pRB 605) under the control of RGP (27) is
shown in Fig. 1. The transgene fragment obtained with XhoI diges-
tion was microinjected into fertilized ova of NOD mice.
Integration of the transgene was detected by PCR using genomic
DNA extracted from tail. To detect chimeric sequences between the
flanking 
 
b
 
-globin sequence and the pTGF-
 
b
 
1 cDNA sequence, pairs
of PCR primers were designed (Fig. 1 and Table I). Primer pairs a, b,
and c amplify DNA sequences of 5
 
9
 
-pTGF-
 
b
 
1, 3
 
9
 
-pTGF-
 
b
 
1, and
RGP, respectively. Primer pairs d and e amplify the Tg pTGF-
 
b
 
1
mRNA, and the 3
 
9
 
-portion of endogenous murine TGF-
 
b
 
1 (mTGF-
 
b
 
1) mRNA, respectively. Primer sequences in these pairs had the 3
 
9
 
-
end and penultimate bases specific to pTGF-
 
b
 
1 and mTGF-
 
b
 
1 se-
quences, respectively. All primer pairs for RT-PCR were designed in
separate exons to cross an intron.
 
PCR detection of pTGF-
 
b
 
1 or mTGF-
 
b
 
1 mRNA in islets.
 
Islets
were isolated from NOD-RGP-TGF-
 
b
 
1, NOD/scid, and NOD mice
at 10 wk of age using a collagenase method as described previously
(28). Total RNA was isolated with ISOGEN (Nippon Gene, Tokyo,
Japan). Total RNA in 1 
 
m
 
g was reverse-transcribed as previously de-
scribed (28). Target sequences were amplified using the first-strand
cDNA as a template after 37 cycles at 94
 
8
 
C for 1 min, 56
 
8
 
C for 1 min,
and 72
 
8
 
C for 2 min. After an extra extension reaction for 8 min, PCR
products were electrophoresed on an 8% polyacrylamide gel. The
amplified DNAs extracted from a polyacrylamide gel by the “crush
and soak” method were subcloned to TA vectors (Invitrogen, San Di-
ego, CA), and the DNA sequences determined with the ABI 377 se-
quencer confirmed their identities of pTGF-
 
b
 
1 or mTGF-
 
b
 
1.
The 
 
b
 
-actin mRNA (which was amplified with a primer set of f;
Table I) was used as an internal control.
 
ELISA and bioassay of TGF-
 
b
 
1.
 
ELISA of the serum of NOD-
Figure 1. Schematic presentation of a 
pTGF-b1 transgene construct. The XhoI-
digested transgene fragment contains a rat 
glucagon promoter (930 bp); a part of rab-
bit b-globin gene exon 2, intron 2, and exon 
3 (640 bp); pTGF-b1 cDNA (1,350 bp); and 
a rabbit b-globin exon 3 and 39-noncoding 
sequence including its poly(A) addition sig-
nal sequence (560 bp). Locations of prim-
ers are shown with arrows.
 
Table I. PCR Primers Used to Amplify Genomic DNA and mRNAs for Cytokines or 
 
b
 
-actin
 
Set
Forward (S) primer
Reverse (A) primer Primer sequence Target (size in bp)
 
a) 1 oRB1669S 5
 
9
 
-GCTGGTTGTTGTGCTGTCTC-3
 
9
 
5
 
9
 
-pTGF-
 
b
 
1 (170)
2 oRB1671A 5
 
9
 
-TGGTCTTGCAGGTGGACAGT-3
 
9
 
1 oRB1669S (as above) 5
 
9
 
-pTGF-
 
b
 
1 (189)
3 oRB2118A 5
 
9
 
-TTCACCAGCTCCATGTCGAT-39
b) 4 oRB1672S 59-AGATCCACTAGTTCTAGAGC-39 39-pTGF-b1 (160)
5 oRB1673A 59-CCAGAAGTCAGATGCTCAAG-39
4 oRB1672S (as above) 39-pTGF-b1 (187)
6 oRB409A 59-TAGCCAGAAGTCAGATGCTC-39
c)  7 oRB1678S 59-TTGGGCGCAGAACACACTCA-39 Rat glucagon exon 1 and rabbit b-globin exon 2 (119)
8 oRB1680A 59-ACTCACCCTGAAGTTCTCAG-39
9 oRB1679S 59-CAAAGTTCCCAAAGGAGCTC-39 Promoter* (101)
8 oRB1680A (as above)
d) 10 oRB627S 59-AGCTTGGATCCTGAGAACTTC-39 pTGF-b1 (180)
2 oRB1671A (as above)
e) oRB2322S 59-CATGAACCGGCCCTTCCTGC-39 mTGF-b1 (348)
oRB2633A 59-CTAGACGATGGGCAGTGGATCCAAA-39
f) oRB1634S 59-GTGGGCCGCTCTAGGCACCA-39 b-actin (245)
oRB1635A 59-CGGTTGGCCTTAGGGTTCAGG39
Primer sets of a, b, and c were used to amplify genomic DNA, and those of d, e, and f were used to amplify mRNAs. *Promoter represents an RGP
sequence. The positions of primers are shown in Fig. 1.
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RGP-TGF-b1 and nontransgenic mice at 16 wk of age was performed
using an ELISA kit (Morinaga, Kanagawa, Japan). The antibody only
detects the active form TGF-b1, including both pTGF-b1 and endog-
enous mTGF-b1 in their active forms. TGF-b1 was assayed before
and after converting TGF-b1 in its latent form into its active form by
acid treatment. In brief, samples and TGF-b1 standards were added
to a 96-well plate, which was coated with anti–TGF-b1 yolk immuno-
globulin (IgY), and incubated at room temperature for 1 h. After
washing, the plate was incubated with biotinylated anti–TGF-b1 IgY.
Peroxidase-conjugated streptavidin and orthophenylene diamine as a
substrate were sequentially added, and the color reaction developed
at room temperature was assessed at the wavelength of 492 nm after
stopping the reaction with 1 N HCl.
Bioassay of TGF-b1 depends on the growth inhibition of mink
lung epithelial cells (Mv1Lu; CCL-64: ATCC) (29) and it detects bio-
activity of TGF-b1 including both pTGF-b1 and endogenous mTGF-
b1 in its active form. The bioassay of TGF-b1 detected the bioactivity
of TGF-b1 in the culture supernatant of 80 islets per one mouse, us-
ing NOD-RGP-TGF-b1 and nontransgenic mice (n 5 6 for each) at
16 wk of age, at 48 h of culture after subtracting that of the culture
medium alone.
Incidence of diabetes in NOD-RGP-TGF-b1 or in NOD mice af-
ter adoptive transfer of splenocytes of NOD-RGP-TGF-b1 mice. In-
cidence of diabetes in NOD-RGP-TGF-b1 and nontransgenic mice
was first followed until 45 wk of age in the natural course. To exam-
ine the resistance of NOD-RGP-TGF-b1 mice against cyclophospha-
mide (CY)-induced diabetes, the incidence of diabetes was then
followed after the administration of 200 mg/kg CY (Shionogi, Osaka,
Japan) twice to six NOD-RGP-TGF-b1 mice including three males
and three females, and six sex-matched littermates at 10 and 12 wk
of age.
To examine the ability of splenocytes of NOD-RGP-TGF-b1
mice to induce diabetes, 2.0–3.0 3 107 splenocytes of female NOD-
RGP-TGF-b1 mice or nondiabetic female littermates at 20 wk of age
were intraperitoneally transferred to NOD mice at 8 d of age. After
37 d of age, the adoptive transfer was performed without sublethal ir-
radiation as previously described (28). Mice were considered diabetic
when nonfasting blood glucose (BG) concentrations were . 14 mM.
Adoptive transfer of diabetogenic splenocytes, CD41, and CD81
clone cells to NOD-RGP-TGF-b1 mice. Diabetogenic splenocytes were
prepared from the spleen of diabetic female NOD mice. To lyse the
red cells, splenocytes were exposed to 0.84% ammonium chloride at
378C for 5 min twice. Remaining cells were washed with PBS and re-
suspended in 150 ml of PBS. Islet b cell–specific CD41 Th1 clones
(4-1-L.6 and 4-1-G.4; abbreviated as L and G) were maintained as
previously described (28, 30). Islet b cell–specific CD81 T cell clones
(G9-C8, TGNF-C8), which were isolated from the lymphocytic infil-
trate in the islets of NOD mice at 7 wk of age (31), were maintained
in Clicks medium (Sigma Chemical Co., St. Louis, MO) supple-
mented with 5% FBS (Hyclone, Logan, UT) and 10 U/ml of recombi-
nant mIL-2 (Becton Dickinson, Bedford, MA) with 2 ml of culture
medium. Proliferation of two CD81 T cell clones was stimulated by
culturing 106 cells of each clone with irradiated dispersed NOD islet
cells as antigen (28) at two weekly intervals.
Three types of lymphocytes, i.e., 0.5–2.0 3 107 diabetogenic sple-
nocytes, 2.0–3.0 3 106 diabetogenic CD41 Th1 clone cells of L or G,
or 2.0–3.0 3 106 diabetogenic CD81 clone cells of G9-C8 or TGNF-
C8, each in 150 ml of PBS, were intraperitoneally transferred to
NOD-RGP-TGF-b1 or nontransgenic mice at 8 d of age. The same
protocol of CY administration and BG determination was performed
as above, and the incidence of diabetes was compared after the adop-
tive transfer of three types of lymphocytes.
Histological analysis and grading of insulitis. Six NOD-RGP-TGF-
b1 mice including three females and three males and six age- and sex-
matched littermates were killed at 10 and 25 wk of age. Pancreas was
excised as described previously (28). More than 100 islets in total per
mouse were analyzed by the uninformed pathologist. The histological
grades of insulitis were evaluated for individual islets using the fol-
lowing criteria on the grade of insulitis from 0 to 3: 0, intact islet with-
out any infiltration; 1, infiltration surrounding or involving , 25% of
the islet area; 2, infiltration involving between 25 and 50% of the islet
area; and 3, infiltration involving . 50% of the islet area. Insulin and
glucagon were stained, respectively, with guinea pig anti–porcine in-
sulin antibody and rat anti–human glucagon antibody (Dako, Glos-
trup, Denmark).
Statistical analysis of insulitis grades and incidence of diabetes.
Student’s unpaired t test was used for the statistical analysis of insuli-
tis grades as previously described (28). For comparing two ratios (Q1,
Q2) of diabetes after the adoptive transfer, a normal distribution
curve, of which mean and variance are Q1 2 Q2 and Q1(1 2 Q1)/n1 1
Q2(1 2 Q2)/n2, respectively, was used (n 5 sample number). P , 0.05
was considered significant.
Results
Generation of NOD-RGP-TGF-b1 mice. Of 48 progeny
screened with PCRs and Southern blot analysis, two female
founder NOD-RGP-TGF-b1 mice were obtained. These two
founders were subsequently bred to NOD mice and two inde-
pendent lines were established. The copy numbers of trans-
gene in two lines of NOD-RGP-TGF-b1 mice were assessed
with semi-quantitative Southern blot analysis as 6 and 10 per
haploid genome, respectively (data not shown).
RT-PCR detection of TGF-b1 mRNA, ELISA and bioas-
say of TGF-b1. The Tg expression of pTGF-b1 was con-
firmed with RT-PCR of the total RNA obtained from islets of
NOD-RGP-TGF-b1 mice. The amplified 180-bp DNA frag-
ment (with a primer set of d) (Table I) was confirmed by se-
Figure 2. RT-PCR detection of Tg pTGF-b1 mRNA or mTGF-b1 
mRNA. Ethidium bromide–stained polyacrylamide gels show
RT-PCR–amplified fragments of pTGF-b1, mTGF-b1, and b-actin 
mRNA. Total RNA in 1 mg isolated from islets of NOD-RGP-TGF-
b1 (A) or NOD/scid mice (B) was reverse-transcribed using random 
hexamer primers. (A) RT-PCR amplification of pTGF-b1 mRNA 
from NOD-RGP-TGF-b1 mice is shown. Lane 1 shows a 180-bp RT-
PCR–amplified pTGF-b1 mRNA as indicated with an arrow. Lane 2 
shows a 245-bp RT-PCR–amplified fragment of b-actin mRNA as a 
control. (B) RT-PCR amplification of mTGF-b1 mRNA from NOD/
scid mice is shown. Lane 1 shows a 348-bp RT-PCR–amplified endog-
enous mTGF-b1 mRNA as indicated with an arrow. Lane 2 shows a 
245-bp RT-PCR–amplified fragment of b-actin mRNA as a control. 
Lane N is the same as lane 1 in A or B except that RTase was omitted 
from the reaction mixture.
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quencing to be derived from pTGF-b1 mRNA after splicing
out the b-globin intron (Fig. 2 A). The endogenous mTGF-b1
mRNA was detected as the 348-bp PCR-amplified fragment in
NOD/scid mice (Fig. 2 B) or NOD mice (data not shown) at
10 wk of age (with a primer set of e), of which identity was con-
firmed by sequencing.
TGF-b1 levels with bioassay of the culture supernatant of
80 islets per one mouse isolated from NOD-RGP-TGF-b1 and
nontransgenic mice (n 5 6 for each) were 211670 and 39649
pg/ml, respectively. The serum levels of TGF-b1 with ELISA
of NOD-RGP-TGF-b1 and nontransgenic mice were 1762.7
and 1562.4 ng/ml (n 5 8 for each) at 16 wk of age, respec-
tively, and they were 3165.6 and 2366.2 ng/ml (n 5 6 for
each) at 60 wk of age, respectively, both without significant dif-
ference.
Incidence of diabetes in the natural course and after CY ad-
ministration. None of 27 NOD-RGP-TGF-b1 mice in two
lines including 8 males plus 10 females from one line and 4
males and 5 females from another line developed diabetes by
45 wk of age (Fig. 3). None of 13 NOD-RGP-TGF-b1 mice in-
cluding 4 males and 9 females became diabetic, even at 60 wk
of age. They were consistently normoglycemic and a mean BG
concentration was 7.7 mM at 45 wk of age. In contrast, female
and male littermates spontaneously started to develop diabe-
tes at 10 and 27 wk of age, respectively, and the cumulative in-
cidence of diabetes (the number of diabetic mice/the total
number of examined mice) was 71% (12/17) in females, and
40% (4/10) in males, respectively, at 45 wk of age. This inci-
dence is comparable to the incidence of diabetes in our NOD
mice colony of 63% (5/8) in female and 25% (2/8) in male
NOD mice at 30 wk of age.
After the administration of CY twice at 10 and 12 wk of
age, five (three females and two males) out of six nontrans-
genic mice (three females and three males) developed overt
diabetes at 17 wk of age and later, but none of six sex-matched
NOD-RGP-TGF-b1 mice developed diabetes even at 20 wk of
age (Fig. 4).
Histological analysis of islets and grading of insulitis.
Most islets of nontransgenic mice exhibited insulitis of grade 1
or 2 (Fig. 5 A), which appeared higher than that in NOD-
RGP-TGF-b1 mice (Fig. 5 D). In contrast, most islets of NOD-
RGP-TGF-b1 mice exhibited no or mild lymphocytic infiltra-
tion of grade 1 (Fig. 5 D), and no acinar change was observed.
No remarkable histology except for insulitis was observed in
NOD-RGP-TGF-b1 mice. To quantitatively assess the histo-
logical grade of insulitis, islets of NOD-RGP-TGF-b1 mice
including three males and three females, and age- and sex-
matched littermates were graded for the severity of insulitis ac-
cording to our criteria. At 10 wk of age, NOD-RGP-TGF-b1
mice had the insulitis score of 0.72 compared with 1.42 in non-
transgenic mice (P , 0.0001) (Table II). The suppression of
mean insulitis grade in NOD-RGP-TGF-b1 mice was associ-
ated with the parallel downward shift in the percentage distri-
bution of islets among four insulitis grades (Table II). At 25 wk
of age, NOD-RGP-TGF-b1 mice had the insulitis score of 0.93
compared with 1.74 in nontransgenic mice (P , 0.0001) (Ta-
ble II). The number and size of islets did not significantly de-
crease from those in nontransgenic mice, as judged by antiin-
sulin immunostaining (Fig. 5, B and E). These islets contained
glucagon-positive cells at an apparently normal ratio (Fig. 5, C
and F).
Incidence of diabetes in NOD mice after adoptive transfer
of splenocytes of NOD-RGP-TGF-b1 mice. The adoptive trans-
fer of splenocytes of female NOD-RGP-TGF-b1 mice from 17
to 19 wk of age to NOD mice at 8 d of age after CY adminis-
tration did not transfer diabetes (0/7), while the adoptive
transfer of splenocytes from age-matched female nondiabetic
NOD mice after CY administration transferred diabetes to
NOD mice (2/6) (P , 0.05). This confirmed the decreased
Figure 3. Time course of the incidence of diabetes in NOD-RGP-
TGF-b1 mice. Time courses of the incidence of diabetes are shown 
for 27 NOD-RGP-TGF-b1 mice including 12 males and 15 females, 
and 27 nontransgenic mice including 10 males and 17 females. Closed 
circles denote NOD-RGP-TGF-b1 mice, open squares and circles de-
note male and female nontransgenic mice, respectively.
Figure 4. Time course of the incidence of diabetes in NOD-RGP-
TGF-b1 mice after CY administration. Time courses of the incidence 
of diabetes are shown for six NOD-RGP-TGF-b1 mice including 
three males and three females, and six nontransgenic mice including 
three males and three females after the administration of CY at 200 
mg/kg at 10 and 12 wk of age, as indicated by arrows. Closed circles 
denote NOD-RGP-TGF-b1 mice, open squares denote nontrans-
genic mice, and numbers in parentheses denote the final incidence of 
diabetes at 17 wk of age.
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ability of splenocytes of NOD-RGP-TGF-b1 mice to induce
diabetes in neonatal NOD mice.
Incidence of diabetes in NOD-RGP-TGF-b1 mice after
adoptive transfer of diabetogenic lymphocytes. As shown in
Fig. 6 and Table III, the incidence of diabetes in nontransgenic
mice at 47 d of age for three types of diabetogenic lymphocytes
was 77% (10/13) for diabetogenic female NOD splenocytes af-
ter CY administration, 75% (6/8) for CD41 Th1 clone cells
after CY administration, and 50% (3/6) for CD81 clone cells
after CY administration. The incidence of diabetes after the
adoptive transfer to nontransgenic mice in regard to two dif-
ferent Th1 clones of L and G, or two different CD81 clones of
G9-C8 and TGNF-C8 was 2/3 and 4/5, or 1/3 and 2/3, respec-
tively.
However, the incidence of diabetes after the adoptive
transfer of three types of diabetogenic lymphocytes to NOD-
RGP-TGF-b1 mice was as low as 29% (2/7) for diabetogenic
splenocytes after CY administration, 25% (2/8) for CD41 Th1
clone cells after CY administration, and 0% (0/6) for CD81
clone cells after CY administration. The incidence of induced
diabetes for each cell type was significantly lower than that in
nontransgenic mice (P , 0.05). No incidence of diabetes was
Figure 5. Histology of pancreas. 
Section of the pancreas from 
NOD-RGP-TGF-b1 mice at
10 wk of age. A–C show the his-
tology of nontransgenic mice, 
while D–F show that of NOD-
RGP-TGF-b1 mice. Hematoxy-
lin and eosin staining shows the 
absence of insulitis in D and in-
sulitis of grade 1.42 in A. B and 
E show insulin staining whereas 
C and F show glucagon staining.
Table II. Percent Distribution of Islets among Four Insulitis Grades
Number
of mice
Percent distribution among insulitis grades
Mean
grade6SD
Number
of isletsGroup Treatment conditions (age) 0 1 2 3 P value (group)
1 Nontransgenic (10 wk) 6 13.6 46.1 26.2 14.1 1.4260.23 119
2 NOD-RGP-TGF-b1 (10 wk) 6 37.6 53.5 8.9 0 0.7260.12 123 P , 0.0001 (1)
3 Nontransgenic (25 wk) 6 0 47.8 29.8 22.4 1.7460.13 178
4 NOD-RGP-TGF-b1 (25 wk) 6 24.8 60.3 13.7 1.2 0.9360.01 157 P , 0.0001 (3)
Group numbers 1 and 3 denote age- and sex-matched nontransgenic mice. P value denotes the significance level in Student’s unpaired t test with data
of the group number indicated in parentheses.
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observed in NOD-RGP-TGF-b1 (0/6) or nontransgenic mice
(0/6) with the administration of PBS plus CY administration.
The incidence of diabetes after the adoptive transfer to NOD-
RGP-TGF-b1 mice in regard to two different Th1 clones of L
and G was 1/3 and 1/5, respectively. These results confirmed
the resistance of NOD-RGP-TGF-b1 mice against three types
of diabetogenic effector lymphocytes.
Discussion
To understand the effect of local paracrine TGF-b1 on au-
toimmune diabetes, we produced NOD-RGP-TGF-b1 mice in
which pTGF-b1 is expressed in islet a cells of NOD mice un-
der the control of the rat glucagon promoter. The higher bio-
activity of TGF-b1 in the islet culture supernatant in NOD-
RGP-TGF-b1 than that of nontransgenic mice confirmed the
local production of bioactive pTGF-b1 in NOD-RGP-TGF-b1
mice. The active form was reported to be 14 times stronger in
bioactivity than the latent pTGF-b1 (24). The ELISA level of
TGF-b1 in the serum before acid treatment was not detect-
able. Total TGF-b1 levels in the serum after acid treatment
were not different between Tg and nontransgenic mice. Al-
though the increase of bioactive pTGF-b1 in the serum could
not be ruled out, pTGF-b1 in NOD-RGP-TGF-b1 mice was
expected to exhibit its major functions in the islet compart-
ment.
In contrast to the complete abrogation of diabetes in two
independent lines of NOD-RGP-TGF-b1 mice without caus-
ing the anatomical distortion in our study, the Tg expression of
pTGF-b1 by the albumin promoter caused the systemic high
concentrations of pTGF-b1 and glomerulosclerosis with the
mesangial proliferation (32). The Tg expression of pTGF-b1
by the insulin promoter had chronic exocrine pancreatitis, ac-
cumulation of extracellular matrix, and disorganization of is-
lets due to the local excessive production of pTGF-b1 in the is-
lets (20, 21). The intact islets (Fig. 5) and the absence of
glomerulosclerosis in our NOD-RGP-TGF-b1 mice (data not
shown) support that the magnitude and duration of local TGF-
b1 levels must be optimum to prevent autoimmune diabetes
without causing morphological changes of islets. This was sup-
ported by the small size of islets in homozygous NOD-RGP-
TGF-b1 mice, which secrete pTGF-b1 in larger amounts than
hemizygous NOD-RGP-TGF-b1 mice, presumably due to the
effects of pTGF-b1 on islet differentiation (data not shown).
The complete abrogation of autoimmune diabetes by Tg
pTGF-b1 in NOD-RGP-TGF-b1 mice and islet b cell trans-
genics for IL-4 in the NOD genetic background (19) are com-
patible with the notion that the autoimmune destruction of is-
let b cells is regulated by the balance between tolerance and its
disruption in the periphery of the islet compartment.
As the protection mechanisms against autoimmune diabe-
tes in NOD mice by local paracrine TGF-b1, direct protection
against effector lymphocytes is most likely. The protective ca-
pacity of TGF-b1 against islet b cell–specific CD41 and CD81
Figure 6. Time course of the incidence of diabetes af-
ter adoptive transfer of three types of diabetogenic 
lymphocytes. (A) The changes in the incidence of dia-
betes after the adoptive transfer of 0.5–2.0 3 107 dia-
betogenic splenocytes after CY administration (filled 
boxes), 2.0–3.0 3 106 diabetogenic CD41 Th1 clone 
cells after CY administration (open boxes) and 2.0–
3.0 3 106 diabetogenic CD81 clone cells after CY ad-
ministration (filled circles) to nontransgenic mice are 
presented. Adoptive transfer was at 8 d of age, non-
fasting BG measurement at 35 and 47 d of age, and 
CY administration at 37 d of age. The incidence of di-
abetes started from 0 in all groups at 8 d of age and 
reached the levels (number of diabetic mice/total 
number of examined mice at 47 d of age) as shown in 
parentheses. (B) The changes in the incidence of dia-
betes after the adoptive transfer of 0.5–2.0 3 107 dia-
betogenic splenocytes after CY administration (filled 
boxes), 2.0–3.0 3 106 diabetogenic CD41 Th1 clone 
cells after CY administration (open boxes), and 2.0–
3.0 3 106 diabetogenic CD81 clone cells after CY ad-
ministration (filled circles) to NOD-RGP-TGF-b1 
mice are presented.
Table III. Incidence of Diabetes in Young NOD-RGP-TGF-b1 
or Nontransgenic Mice after the Adoptive Transfer of Three 
Types of Diabetogenic Lymphocytes
Adoptively transferred
lymphocytes
LM
or Tg
Number
of mice
Incidence of
transferred
diabetes (%)
Statistical
significance
Diabetic splenocytes LM 13 10/13 (77%)
Diabetic splenocytes Tg 7 2/7 (29%) P , 0.05
G or L CD41 clone LM 8 6/8 (75%)
G or L CD41 clone Tg 8 2/8 (25%) P , 0.05
CD81 clones LM 6 3/6 (50%)
CD81 clones Tg 6 0/6 (0%) P , 0.05
PBS LM 6 0/6 (0%)
PBS Tg 6 0/6 (0%)
LM and Tg stand for nontransgenic mice and NOD-RGP-TGF-b1 mice.
Statistical significance was examined between LM and Tg.
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effector lymphocytes is expected to disrupt the vicious cycle of
antigen presentation after islet b cell destruction and function
as the most likely protection mechanism. The decreased gener-
ation of autoreactive T cells and the generation of regulatory T
cells may afford possible mechanisms of protection.
The majority of islet-infiltrating lymphocytes expressing
TGF-b1, IL-4, and IL-10 was reported to contribute to the tol-
erance induced by oral insulin against LCMV-induced insulitis
and diabetes (18). IL-10 in vitro induces differentiation of anti-
gen-specific CD41 regulatory T cell subset of Tr1 which se-
cretes IL-10 and TGF-b1, and Tr1 suppresses experimental au-
toimmune colitis induced by pathogenic CD41 CD45RBhigh
splenic T cells (33). The adoptive transfer of islet-infiltrating
autoreactive CD81 cell clone of I.S. 2.15 (34) or CD41 sup-
pressor T cell clone of NY4.2 (35), both secreting TGF-b1,
prevents autoimmune diabetes in NOD mice. These observa-
tions suggest the importance of local TGF-b1 itself and regula-
tory T cell subsets secreting TGF-b1 in preventing autoimmune
colitis and diabetes. The possible induction of antigen-specific
regulatory T cell subsets in NOD-RGP-TGF-b1 mice is being
tested by the cotransfer experiment in our laboratory.
Decreased mean insulitis grades in NOD-RGP-TGF-b1
mice (Table II) suggest the suppressed generation of islet b
cell–specific autoimmune lymphocytes in NOD-RGP-TGF-b1
mice, which is consistent with the resistance of NOD-RGP-
TGF-b1 mice against CY-induced diabetes and inability of
splenocytes of NOD-RGP-TGF-b1 mice to transfer diabetes
to neonatal NOD mice. Activation of autoreactive T cells may
be directly suppressed by the local high concentrations of
TGF-b1 in parallel with the suppressed activation of effector T
cells and the protection against effector T cells.
In addition to TGF-b1, Th2 cytokines such as IL-4 (19) and
IL-10 (27) have been known to suppress autoimmune diabetes.
IL-4 induces differentiation of Th0 cells to Th2 cells, while
IFN-g and IL-12 induce differentiation of Th0 cells to Th1 cells
(36–38). TGF-b1 may prevent autoimmune diabetes in NOD
mice through shifting the Th1/Th2 balance toward Th2, al-
though Th2 induction by TGF-b1 has not been reported. The
inability of TGF-b1 to suppress LCMV-induced autoimmune
insulitis and diabetes in islet b cell double transgenics for
LCMV GP protein and TGF-b1 (22) might be due to the ex-
cessive autocrine TGF-b1.
Islet b cell transgenics for TGF-b1 were reported not to
suppress allograft rejection (22). However, the protective role
of Tg paracrine TGF-b1 in our NOD-RGP-TGF-b1 mice and
the supposed essential role of TGF-b1 in suppressing EAE
(11), autoimmune diabetes (34, 35), and autoimmune colitis
(33) strongly suggest that the islet isografts or allografts can be
tolerized by the appropriate amount of local paracrine TGF-b1.
Because adoptive transfer of IL-10– or IL-4–transduced Th1
lymphocytes prevents autoimmune diabetes (28) or EAE (39),
respectively, the molecular transduction of antigen-specific T
cells or grafts before transplantation with the TGF-b1 gene is
expected to afford us an animal model of gene therapy for
autoimmune diseases and graft survival, respectively. The im-
plication for the long-term survival of islet isografts from
NOD-RGP-TGF-b1 to NOD mice is being tested by the trans-
plantation experiment in our laboratory.
The NOD-RGP-TGF-b1 mouse is one of only two avail-
able Tg models which completely prevent autoimmune diabe-
tes in NOD mice by the Tg cytokine expression in the islet
compartment, with another being islet b cell transgenics for
IL-4 (19). The NOD-RGP-TGF-b1 mouse thus affords us an
important animal model to study the protective role of local
paracrine TGF-b1 against autoimmune diabetes. Based on our
results, we concluded that autoimmune diabetes in NOD mice
is not a systemic disease, and that it can be completely pre-
vented by the Tg paracrine TGF-b1 in the islet compartment.
The protection by local paracrine TGF-b1 against autoim-
mune diabetes is mediated by the protection against CD41 and
CD81 effector lymphocytes.
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